董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joel Lewis | 男 | Chief Executive Officer, President and Director | 56 | 117.48万美元 | 162.74 | 2026-10-13 |
| Richard E. Uihlein | 男 | Chairman and Independent Director | 80 | 9.23万美元 | 5483.14 | 2026-10-13 |
| Elissa J. Schwartz | 女 | Independent Director | 56 | 9.58万美元 | 30.10 | 2026-10-13 |
| Richard A. Zordani | 男 | Independent Director | 54 | 10.73万美元 | 34.49 | 2026-10-13 |
| Henry Brem | 男 | Independent Director | 73 | 未披露 | 未持股 | 2026-10-13 |
| Gilbert S. Omenn | 男 | Independent Director | 85 | 10.23万美元 | 54.80 | 2026-10-13 |
| Gilbert F. Amelio | 男 | Independent Director | 83 | 10.78万美元 | 43.56 | 2026-10-13 |
| Kary Eldred | 男 | Independent Director | 52 | 9.98万美元 | 90.35 | 2026-10-13 |
| Kevin D. Freeman | 男 | Independent Director | 65 | 10.83万美元 | 83.50 | 2026-10-13 |
| Benjamin S. Carson, Sr. | 男 | Independent Director | 74 | 9.23万美元 | 21.00 | 2026-10-13 |
| Harold H. Shlevin | 男 | Independent Director | 76 | 9.23万美元 | 41.15 | 2026-10-13 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joel Lewis | 男 | Chief Executive Officer, President and Director | 56 | 117.48万美元 | 162.74 | 2026-10-13 |
| Khurram Jamil | 男 | Chief Medical Officer | 50 | 105.21万美元 | 6.63 | 2026-10-13 |
| Jack W. Callicutt | 男 | Chief Financial Officer | 58 | 80.66万美元 | 55.14 | 2026-10-13 |
董事简历
中英对照 | 中文 | 英文- Joel Lewis
-
Joel Lewis，自2017年起担任董事，于2020年9月2日成为我们的总裁兼首席执行官。此前，他曾担任Uline，Inc.（航运，包装和工业用品的分销商）的股东服务董事总经理，他于2007年至2019年担任该职位。Lewis先生是一名财务执行官，拥有超过26年的经验，于1992年开始了他的公共会计职业生涯。任职Uline Inc.之前，Lewis从2001年到2006年担任Century America LLC税务和会计经理，从1998年到2001年担任Deloitte&Touche税务经理。Lewis先生在公共会计领域工作了十年，在那里他专注于财务报告和税收，之后他移民到专注于高净值家族企业的私人控股公司。Lewis先生拥有广泛的专业知识，包括在各种行业和学科工作，包括税收，重组，收购和私募股权投资。Lewis先生是伊利诺斯州的注册会计师。他持有the University of Illinois的会计学士学位，以及DePaul University的税务硕士学位。
Joel Lewis a director since 2017, became Galectin Therapeutics Inc. President and Chief Executive Officer on September 2, 2020. Previously, he was the Managing Director of Shareholder Services at Uline, Inc. (a distributor of shipping, packaging and industrial supplies), a position he held from 2007 through 2019. Mr. Lewis is a financial executive with over 26 years of experience and started his career in public accounting in 1992. Prior to his employment with Uline Inc., Mr. Lewis served as a Tax and Accounting Manager for Century America LLC from 2001 to 2006 and a Tax Manager for Deloitte & Touche from 1998 to 2001. After spending a decade in public accounting where he specialized in both financial reporting and taxation, Mr. Lewis migrated to privately held companies focusing on high net worth family businesses. Mr. Lewis has a wide range of expertise including working in a variety of industries and disciplines including taxation, restructuring, acquisition and private equity ventures. Mr. Lewis is a registered CPA in the state of Illinois. He holds a B.S. in Accountancy from the University of Illinois and a Masters in Taxation from DePaul University. - Joel Lewis，自2017年起担任董事，于2020年9月2日成为我们的总裁兼首席执行官。此前，他曾担任Uline，Inc.（航运，包装和工业用品的分销商）的股东服务董事总经理，他于2007年至2019年担任该职位。Lewis先生是一名财务执行官，拥有超过26年的经验，于1992年开始了他的公共会计职业生涯。任职Uline Inc.之前，Lewis从2001年到2006年担任Century America LLC税务和会计经理，从1998年到2001年担任Deloitte&Touche税务经理。Lewis先生在公共会计领域工作了十年，在那里他专注于财务报告和税收，之后他移民到专注于高净值家族企业的私人控股公司。Lewis先生拥有广泛的专业知识，包括在各种行业和学科工作，包括税收，重组，收购和私募股权投资。Lewis先生是伊利诺斯州的注册会计师。他持有the University of Illinois的会计学士学位，以及DePaul University的税务硕士学位。
- Joel Lewis a director since 2017, became Galectin Therapeutics Inc. President and Chief Executive Officer on September 2, 2020. Previously, he was the Managing Director of Shareholder Services at Uline, Inc. (a distributor of shipping, packaging and industrial supplies), a position he held from 2007 through 2019. Mr. Lewis is a financial executive with over 26 years of experience and started his career in public accounting in 1992. Prior to his employment with Uline Inc., Mr. Lewis served as a Tax and Accounting Manager for Century America LLC from 2001 to 2006 and a Tax Manager for Deloitte & Touche from 1998 to 2001. After spending a decade in public accounting where he specialized in both financial reporting and taxation, Mr. Lewis migrated to privately held companies focusing on high net worth family businesses. Mr. Lewis has a wide range of expertise including working in a variety of industries and disciplines including taxation, restructuring, acquisition and private equity ventures. Mr. Lewis is a registered CPA in the state of Illinois. He holds a B.S. in Accountancy from the University of Illinois and a Masters in Taxation from DePaul University.
- Richard E. Uihlein
-
RichardE.Uihlein自2017年起担任董事，自2018年5月起担任董事长，于1980年共同创立了领先的航运，包装和工业用品分销商Uline，Inc.，并自成立以来一直担任其首席执行官兼董事长。创立Uline Inc.之前，Uihlein从1967年到1980年在General Bindings Corp.，Northbrook，IL任职。Uihlein先生毕业于加利福尼亚州帕洛阿尔托的斯坦福大学（Stanford University）。1967年获历史学学士学位。
Richard E. Uihlein a director since 2017 and Chairman since May 2018, co founded Uline, Inc. (a leading distributor of shipping, packaging and industrial supplies) in 1980, and has served as its Chief Executive Officer and Chairman since its founding. Prior to founding Uline Inc., Mr. Uihlein was employed at General Bindings Corp., Northbrook, IL from 1967 to 1980. Mr. Uihlein graduated from Stanford University, Palo Alto, CA. with a BA degree in history in 1967. - RichardE.Uihlein自2017年起担任董事，自2018年5月起担任董事长，于1980年共同创立了领先的航运，包装和工业用品分销商Uline，Inc.，并自成立以来一直担任其首席执行官兼董事长。创立Uline Inc.之前，Uihlein从1967年到1980年在General Bindings Corp.，Northbrook，IL任职。Uihlein先生毕业于加利福尼亚州帕洛阿尔托的斯坦福大学（Stanford University）。1967年获历史学学士学位。
- Richard E. Uihlein a director since 2017 and Chairman since May 2018, co founded Uline, Inc. (a leading distributor of shipping, packaging and industrial supplies) in 1980, and has served as its Chief Executive Officer and Chairman since its founding. Prior to founding Uline Inc., Mr. Uihlein was employed at General Bindings Corp., Northbrook, IL from 1967 to 1980. Mr. Uihlein graduated from Stanford University, Palo Alto, CA. with a BA degree in history in 1967.
- Elissa J. Schwartz
-
Elissa J.Schwartz，董事会于2020年9月任命的董事，是疾病模型师，现任华盛顿州立大学WSU生物科学和数学教授。她在Mount Sinai-NYU获得生物医学科学博士学位，在UC Berkeley获得数学学士学位，在UCLA获得生物数学和生物统计学跨学科博士后培训。她还隶属于WSU兽医学院（the WSU College of Veterinary Medicine）的微生物学和病理学，目前她在WSU COVID-19建模工作队任职。Schwartz博士是30多篇关于传染病、免疫反应和生物建模的科学出版物的作者。她任职于the Society for Mathematical Biology的董事会，此前她曾担任Pharmerit International，LP（药物经济学公司）的顾问。Schwartz博士曾在俄亥俄州立大学数学生物科学研究所（Ohio State University）和南非开普敦非洲数学科学研究所（African Institute for Mathematical Sciences）获得研究金，并在印度British Columbia和尼泊尔的教学学院任职。
Elissa J. Schwartz a director appointed by the board in September 2020, is a disease modeler who is currently a professor of biological sciences and mathematics at Washington State University (WSU). She received a PhD in Biomedical Sciences from Mount Sinai–NYU, a BA in Mathematics from UC Berkeley, and interdisciplinary postdoctoral training in Biomathematics and Biostatistics from UCLA. She is also affiliated with the WSU College of Veterinary Medicine in microbiology and pathology. Dr. Schwartz is the author of over 45 scientific publications on infectious disease, the immune response, and biological modeling. She has served on the Board of Directors for the Society for Mathematical Biology, and she previously consulted for Pharmerit International, (now OPEN Health), a global pharmaceutical economics company. Dr. Schwartz has held fellowships with the Mathematical Biosciences Institute (Ohio State University) and the African Institute for Mathematical Sciences (Cape Town, South Africa), and she served on the teaching faculty for courses in British Columbia, India, and Nepal. - Elissa J.Schwartz，董事会于2020年9月任命的董事，是疾病模型师，现任华盛顿州立大学WSU生物科学和数学教授。她在Mount Sinai-NYU获得生物医学科学博士学位，在UC Berkeley获得数学学士学位，在UCLA获得生物数学和生物统计学跨学科博士后培训。她还隶属于WSU兽医学院（the WSU College of Veterinary Medicine）的微生物学和病理学，目前她在WSU COVID-19建模工作队任职。Schwartz博士是30多篇关于传染病、免疫反应和生物建模的科学出版物的作者。她任职于the Society for Mathematical Biology的董事会，此前她曾担任Pharmerit International，LP（药物经济学公司）的顾问。Schwartz博士曾在俄亥俄州立大学数学生物科学研究所（Ohio State University）和南非开普敦非洲数学科学研究所（African Institute for Mathematical Sciences）获得研究金，并在印度British Columbia和尼泊尔的教学学院任职。
- Elissa J. Schwartz a director appointed by the board in September 2020, is a disease modeler who is currently a professor of biological sciences and mathematics at Washington State University (WSU). She received a PhD in Biomedical Sciences from Mount Sinai–NYU, a BA in Mathematics from UC Berkeley, and interdisciplinary postdoctoral training in Biomathematics and Biostatistics from UCLA. She is also affiliated with the WSU College of Veterinary Medicine in microbiology and pathology. Dr. Schwartz is the author of over 45 scientific publications on infectious disease, the immune response, and biological modeling. She has served on the Board of Directors for the Society for Mathematical Biology, and she previously consulted for Pharmerit International, (now OPEN Health), a global pharmaceutical economics company. Dr. Schwartz has held fellowships with the Mathematical Biosciences Institute (Ohio State University) and the African Institute for Mathematical Sciences (Cape Town, South Africa), and she served on the teaching faculty for courses in British Columbia, India, and Nepal.
- Richard A. Zordani
-
RichardA.Zordani，董事会于2020年9月任命的董事，自2013年以来一直担任Uline，Inc.（航运，包装和工业用品的分销商）的股东服务总监。在加入Uline之前，佐尔达尼曾担任多元化金融管理公司（Diversified Financial Management Corp.，Pritzker Family Office）的董事兼Vice President，2003年至2013年，他在该公司为国内外实体和信托基金提供复杂的法律和税收结构方面的咨询，并担任Altshuler的审计经理，从1996年到2003年，Melvoin&Glasser LLP（现为RSM McGladrey）。佐尔达尼先生在伊利诺伊大学厄巴纳/香槟分校（University of Illinois at Urbana/Champaign）获得本科学位，是伊利诺斯州的注册会计师。
Richard A. Zordani a director appointed by the board in September 2020, has been the Director of Shareholder Services at Uline, Inc. (a distributor of shipping, packaging and industrial supplies) since 2013. Prior to joining Uline, Mr. Zordani served as a Director and Vice President for Diversified Financial Management Corp. (Pritzker family office) where he advised on complex legal and tax structures for domestic and foreign entities and trusts from 2003 through 2013 and an Audit Manager for Altschuler, Melvoin & Glasser LLP (now RSM McGladrey) from 1996 through 2003. Mr. Zordani received his undergraduate degree from the University of Illinois at Urbana/Champaign and is a Registered CPA in the state of Illinois. - RichardA.Zordani，董事会于2020年9月任命的董事，自2013年以来一直担任Uline，Inc.（航运，包装和工业用品的分销商）的股东服务总监。在加入Uline之前，佐尔达尼曾担任多元化金融管理公司（Diversified Financial Management Corp.，Pritzker Family Office）的董事兼Vice President，2003年至2013年，他在该公司为国内外实体和信托基金提供复杂的法律和税收结构方面的咨询，并担任Altshuler的审计经理，从1996年到2003年，Melvoin&Glasser LLP（现为RSM McGladrey）。佐尔达尼先生在伊利诺伊大学厄巴纳/香槟分校（University of Illinois at Urbana/Champaign）获得本科学位，是伊利诺斯州的注册会计师。
- Richard A. Zordani a director appointed by the board in September 2020, has been the Director of Shareholder Services at Uline, Inc. (a distributor of shipping, packaging and industrial supplies) since 2013. Prior to joining Uline, Mr. Zordani served as a Director and Vice President for Diversified Financial Management Corp. (Pritzker family office) where he advised on complex legal and tax structures for domestic and foreign entities and trusts from 2003 through 2013 and an Audit Manager for Altschuler, Melvoin & Glasser LLP (now RSM McGladrey) from 1996 through 2003. Mr. Zordani received his undergraduate degree from the University of Illinois at Urbana/Champaign and is a Registered CPA in the state of Illinois.
- Henry Brem
-
亨利·布雷姆自2026年起担任董事，是国际公认的神经外科科学家和转化医学领域的领导者。他担任约翰霍普金斯大学神经外科亨利·布雷姆教授，此前曾在2000年至2025年期间担任约翰霍普金斯医疗机构神经外科主任和首席神经外科医生。他还是Sidney Kimmel综合癌症中心脑癌项目的联合主任。Brem博士通过开发图像引导手术技术和本地化药物递送系统，包括Gliadel，帮助改变了神经外科肿瘤学脑瘤的晶片。他发表了超过416篇同行评审论文，拥有多项专利，四十多年来持续获得美国国立卫生研究院的资助。他是美国国家医学研究院的成员，获得了无数荣誉，以表彰他对临床卓越和转化研究的贡献。布雷姆博士曾担任多家私营和上市公司的董事。
Henry Brem a director since 2026, is an internationally recognized neurosurgeon scientist and leader in translational medicine. He serves as the Henry Brem Professor of Neurosurgery at Johns Hopkins University and previously served from 2000 until 2025 as Director of the Department of Neurosurgery and Neurosurgeon in Chief at The Johns Hopkins Medical Institutions. He is also Co Director of the Brain Cancer Program at the Sidney Kimmel Comprehensive Cancer Center. Dr. Brem has helped transform neurosurgical oncology through the development of image guided surgical techniques and localized drug delivery systems, including Gliadel wafers for brain tumors. He has published more than 416 peer reviewed papers, holds multiple patents, and has been continuously funded by the NIH for over four decades. He is a member of the National Academy of Medicine and has received numerous honors recognizing his contributions to clinical excellence and translational research. Dr. Brem has served as director for multiple private and public companies. - 亨利·布雷姆自2026年起担任董事，是国际公认的神经外科科学家和转化医学领域的领导者。他担任约翰霍普金斯大学神经外科亨利·布雷姆教授，此前曾在2000年至2025年期间担任约翰霍普金斯医疗机构神经外科主任和首席神经外科医生。他还是Sidney Kimmel综合癌症中心脑癌项目的联合主任。Brem博士通过开发图像引导手术技术和本地化药物递送系统，包括Gliadel，帮助改变了神经外科肿瘤学脑瘤的晶片。他发表了超过416篇同行评审论文，拥有多项专利，四十多年来持续获得美国国立卫生研究院的资助。他是美国国家医学研究院的成员，获得了无数荣誉，以表彰他对临床卓越和转化研究的贡献。布雷姆博士曾担任多家私营和上市公司的董事。
- Henry Brem a director since 2026, is an internationally recognized neurosurgeon scientist and leader in translational medicine. He serves as the Henry Brem Professor of Neurosurgery at Johns Hopkins University and previously served from 2000 until 2025 as Director of the Department of Neurosurgery and Neurosurgeon in Chief at The Johns Hopkins Medical Institutions. He is also Co Director of the Brain Cancer Program at the Sidney Kimmel Comprehensive Cancer Center. Dr. Brem has helped transform neurosurgical oncology through the development of image guided surgical techniques and localized drug delivery systems, including Gliadel wafers for brain tumors. He has published more than 416 peer reviewed papers, holds multiple patents, and has been continuously funded by the NIH for over four decades. He is a member of the National Academy of Medicine and has received numerous honors recognizing his contributions to clinical excellence and translational research. Dr. Brem has served as director for multiple private and public companies.
- Gilbert S. Omenn
-
Gilbert S. Omenn，自2020年3月起担任Amesite Inc.董事会成员。在被任命为董事会成员之前，他曾担任Amesite Inc.的顾问董事会成员。Omenn博士是密歇根大学计算医学和生物信息学、内科、人类遗传学和公共卫生的Harold T. Shapiro杰出大学教授。他拥有数十年的上市公司董事会经验，包括在Amgen公司（纳斯达克股票代码：AMGN）工作27年，在Rohm & Haas公司工作22年。他曾担任华盛顿大学公共卫生与社区医学院院长（1982-1997），随后担任密歇根大学医疗事务执行副总裁和密歇根大学卫生系统首席执行官（1997-2002）。此外，他还是原子能委员会的白宫研究员（1973-1974），白宫科技政策办公室和管理与预算办公室的副主任（1977-1981），美国科学促进会“2061计划”的顾问委员会成员。“面向全体美国人的科学”（1986-1996），总统/国会风险评估与风险管理委员会主席（1994-1997），美国科学促进会主席（AAAS， 2006），美国国立卫生研究院科学管理审查委员会成员（2012-2014），美国国家医学院理事会成员（NAM， 2015-2017），目前是美国国家科学院政策与全球事务委员会成员。他是Angion Biomedica和Galectin Therapeutics的董事。
Gilbert S. Omenn has served as a member of Amesite Inc.'s board of directors since March 2020. Prior to his appointment as a member of the board of directors, Dr. Omenn served on Amesite Inc.'s board of advisors. Dr. Omenn is the Harold T. Shapiro Distinguished University Professor of Computational Medicine & Bioinformatics, Internal Medicine, Human Genetics, and Public Health at the University of Michigan. Dr. Omenn brings decades of public company board experience, including 27 years with Amgen, Inc, (NASDAQ: AMGN) and 22 years with Rohm & Haas Company. He was Dean of the University of Washington School of Public Health & Community Medicine (1982 1997) and then Executive Vice President for Medical Affairs at the University of Michigan and CEO of the UM Health System (1997 2002). In addition, he was a White House Fellow at the Atomic Energy Commission (1973 1974), Associate Director of the White House Office of Science & Technology Policy and the Office of Management and Budget (1977 1981), on the advisory council for the AAAS "Project 2061: Science for all Americans" (1986 1996), chair of the Presidential/Congressional Commission on Risk Assessment & Risk Management (1994 1997), President of the American Association for the Advancement of Science (AAAS, 2006), member of the Scientific Management Review Board for the NIH (2012 2014), member of the Council of the National Academy of Medicine (NAM, 2015 2017), and currently a member of the Policy & Global Affairs Committee of the National Academies. He is a director of Angion Biomedica and of Galectin Therapeutics. - Gilbert S. Omenn，自2020年3月起担任Amesite Inc.董事会成员。在被任命为董事会成员之前，他曾担任Amesite Inc.的顾问董事会成员。Omenn博士是密歇根大学计算医学和生物信息学、内科、人类遗传学和公共卫生的Harold T. Shapiro杰出大学教授。他拥有数十年的上市公司董事会经验，包括在Amgen公司（纳斯达克股票代码：AMGN）工作27年，在Rohm & Haas公司工作22年。他曾担任华盛顿大学公共卫生与社区医学院院长（1982-1997），随后担任密歇根大学医疗事务执行副总裁和密歇根大学卫生系统首席执行官（1997-2002）。此外，他还是原子能委员会的白宫研究员（1973-1974），白宫科技政策办公室和管理与预算办公室的副主任（1977-1981），美国科学促进会“2061计划”的顾问委员会成员。“面向全体美国人的科学”（1986-1996），总统/国会风险评估与风险管理委员会主席（1994-1997），美国科学促进会主席（AAAS， 2006），美国国立卫生研究院科学管理审查委员会成员（2012-2014），美国国家医学院理事会成员（NAM， 2015-2017），目前是美国国家科学院政策与全球事务委员会成员。他是Angion Biomedica和Galectin Therapeutics的董事。
- Gilbert S. Omenn has served as a member of Amesite Inc.'s board of directors since March 2020. Prior to his appointment as a member of the board of directors, Dr. Omenn served on Amesite Inc.'s board of advisors. Dr. Omenn is the Harold T. Shapiro Distinguished University Professor of Computational Medicine & Bioinformatics, Internal Medicine, Human Genetics, and Public Health at the University of Michigan. Dr. Omenn brings decades of public company board experience, including 27 years with Amgen, Inc, (NASDAQ: AMGN) and 22 years with Rohm & Haas Company. He was Dean of the University of Washington School of Public Health & Community Medicine (1982 1997) and then Executive Vice President for Medical Affairs at the University of Michigan and CEO of the UM Health System (1997 2002). In addition, he was a White House Fellow at the Atomic Energy Commission (1973 1974), Associate Director of the White House Office of Science & Technology Policy and the Office of Management and Budget (1977 1981), on the advisory council for the AAAS "Project 2061: Science for all Americans" (1986 1996), chair of the Presidential/Congressional Commission on Risk Assessment & Risk Management (1994 1997), President of the American Association for the Advancement of Science (AAAS, 2006), member of the Scientific Management Review Board for the NIH (2012 2014), member of the Council of the National Academy of Medicine (NAM, 2015 2017), and currently a member of the Policy & Global Affairs Committee of the National Academies. He is a director of Angion Biomedica and of Galectin Therapeutics.
- Gilbert F. Amelio
-
Gilbert F. Amelio从2011年3月开始一直担任公司的董事。他在领先的技术公司拥有长达几十年的担任执行领导职位的职业经历，包括苹果电脑（Apple Computer）的首席执行官兼董事会主席；美国国家半导体（National Semiconductor）的总裁、首席执行官兼董事会主席；并担任罗克韦尔通信系统（Rockwell Communication Systems）的总裁，其为罗克韦尔国际公司（Rockwell International）的一个业务单元。从2001年到2011年12月，担任Sienna Ventures, LLC的高级合伙人，该公司是一家风险投资公司，从2005年开始担任GFA, LLC的负责人，这是一家咨询公司，并从2009年开始担任Alteon Capital Partners, LLC的合伙人，该公司是一家咨询公司。从2005年到2008年，Amelio博士担任范围广泛的技术风投公司的领导职位或参与公司创立，包括Jazz Technologies, Inc.，这是一家由他创立的上市半导体芯片代工公司，他在该公司担任董事会主席兼首席执行官，还包括Acquicor Management LLC，该公司是Jazz Technologies的前股东。Acquicor Management于2008年宣告破产。AmTech, LLC于2003年宣告破产，这是一家高技术投资与咨询服务公司，Amelio博士在该公司从1999年到2004年担任董事会主席兼首席执行官。Amelio博士是美国技术行业的先驱者，他在美国电话电报公司贝尔实验（AT&T Bell Laboratories）和飞兆半导体公司（Fairchild Semiconductor）开启职业生涯。作为美国半导体产业协会（Semiconductor Industry Association）的董事兼董事会主席，Amelio博士担任美国电子工业协会（Electronics Industries Association）的理事，并是商业和高等教育论坛（Business and Higher Education Forum）的执行委员会委员。他还担任Galectin Therapeutics Inc的董事会董事，以前叫做Pro-Pharmaceuticals, Inc. （从2009年开始），并在美国电报电话公司（AT&T Inc.）服务18年后于2013年从该公司的董事会退休。
Gilbert F. Amelio a director since February 2009, began his career at Bell Labs in Murray Hill, New Jersey. Since January 1, 2012, Dr. Amelio has provided consulting and advisory services through GFA, LLC, a California limited liability company. He was a Senior Partner of Sienna Ventures (a privately held venture capital firm in Sausalito, California) from April 2001 until the fund closed per plan on December 31, 2011. Dr. Amelio was Chairman and Chief Executive Officer of Jazz Technologies, Inc. (now a wholly owned subsidiary of Tower Semiconductor Ltd., an independent specialty wafer foundry) from August 2005 until his retirement in September 2008 (when he was named Chairman Emeritus). Dr. Amelio was Chairman and Chief Executive Officer of Beneventure Capital, LLC (a full service venture capital firm in San Francisco, California) from 1999 to 2005 and was Principal of Aircraft Ventures, LLC (a consulting firm in Newport Beach, California) from April 1997 to December 2004. Dr. Amelio was elected a Director of AT&T in February 2001 and had previously served as an Advisory Director of AT&T (then known as SBC Communications Inc.) from April 1997 to February 2001. He served as a Director of Pacific Telesis Group from 1995 until the company was acquired by AT&T in 1997. Prior to 1997, he served as Chairman, President and CEO of National Semiconductor (1991 1996) and Apple Computer (1996 1997). - Gilbert F. Amelio从2011年3月开始一直担任公司的董事。他在领先的技术公司拥有长达几十年的担任执行领导职位的职业经历，包括苹果电脑（Apple Computer）的首席执行官兼董事会主席；美国国家半导体（National Semiconductor）的总裁、首席执行官兼董事会主席；并担任罗克韦尔通信系统（Rockwell Communication Systems）的总裁，其为罗克韦尔国际公司（Rockwell International）的一个业务单元。从2001年到2011年12月，担任Sienna Ventures, LLC的高级合伙人，该公司是一家风险投资公司，从2005年开始担任GFA, LLC的负责人，这是一家咨询公司，并从2009年开始担任Alteon Capital Partners, LLC的合伙人，该公司是一家咨询公司。从2005年到2008年，Amelio博士担任范围广泛的技术风投公司的领导职位或参与公司创立，包括Jazz Technologies, Inc.，这是一家由他创立的上市半导体芯片代工公司，他在该公司担任董事会主席兼首席执行官，还包括Acquicor Management LLC，该公司是Jazz Technologies的前股东。Acquicor Management于2008年宣告破产。AmTech, LLC于2003年宣告破产，这是一家高技术投资与咨询服务公司，Amelio博士在该公司从1999年到2004年担任董事会主席兼首席执行官。Amelio博士是美国技术行业的先驱者，他在美国电话电报公司贝尔实验（AT&T Bell Laboratories）和飞兆半导体公司（Fairchild Semiconductor）开启职业生涯。作为美国半导体产业协会（Semiconductor Industry Association）的董事兼董事会主席，Amelio博士担任美国电子工业协会（Electronics Industries Association）的理事，并是商业和高等教育论坛（Business and Higher Education Forum）的执行委员会委员。他还担任Galectin Therapeutics Inc的董事会董事，以前叫做Pro-Pharmaceuticals, Inc. （从2009年开始），并在美国电报电话公司（AT&T Inc.）服务18年后于2013年从该公司的董事会退休。
- Gilbert F. Amelio a director since February 2009, began his career at Bell Labs in Murray Hill, New Jersey. Since January 1, 2012, Dr. Amelio has provided consulting and advisory services through GFA, LLC, a California limited liability company. He was a Senior Partner of Sienna Ventures (a privately held venture capital firm in Sausalito, California) from April 2001 until the fund closed per plan on December 31, 2011. Dr. Amelio was Chairman and Chief Executive Officer of Jazz Technologies, Inc. (now a wholly owned subsidiary of Tower Semiconductor Ltd., an independent specialty wafer foundry) from August 2005 until his retirement in September 2008 (when he was named Chairman Emeritus). Dr. Amelio was Chairman and Chief Executive Officer of Beneventure Capital, LLC (a full service venture capital firm in San Francisco, California) from 1999 to 2005 and was Principal of Aircraft Ventures, LLC (a consulting firm in Newport Beach, California) from April 1997 to December 2004. Dr. Amelio was elected a Director of AT&T in February 2001 and had previously served as an Advisory Director of AT&T (then known as SBC Communications Inc.) from April 1997 to February 2001. He served as a Director of Pacific Telesis Group from 1995 until the company was acquired by AT&T in 1997. Prior to 1997, he served as Chairman, President and CEO of National Semiconductor (1991 1996) and Apple Computer (1996 1997).
- Kary Eldred
-
Kary Eldred自2018年起担任Living Stone Foundation董事，自2015年7月起担任首席投资官，多年来一直是活跃的私募股权投资者。在这些职位上，他曾担任多家具有首次公开募股潜力并推动其发展的公司的董事会成员，目前担任Buy IT Installing（2017年以来）和Wise King Media（2015年以来）的董事会成员。Kary Eldred也曾任职于GCT Semiconductor的董事会和审计委员会。从2011年1月到2014年10月，Eldred先生担任Altadona，S.A.的首席执行官兼董事长，这是一家位于欧洲的软件集成公司，在此之前，他是Parakletos Ventures的负责人，一家机构风险投资公司，对在纳斯达克，科斯达克和创业板市场等全球不同交易所被收购或公开上市的公司进行了多项投资。Eldred先生拥有IE Business School的执行工商管理硕士学位和Baylor University的外交服务学士学位。
Kary Eldred is a director since 2018 and Chief Investment Officer for the Living Stones Foundation since July 2015 and has been an active private equity investor for many years. In these capacities, he serves and has served on a number of corporate boards of companies with potential for and driving toward initial public offerings and is currently serving as a board member in Buy It Installed (since 2017), Babywise and Wise King Media (since 2015). Kary Eldred also served on the board and audit committee of GCT Semiconductor. From January 2011 through October 2014, Mr. Eldred was CEO & Chairman of Altadona, S.A. a software integration company based in Europe and prior to that was a principal in Parakletos Ventures, an institutional venture capital firm with several investments in companies that went on to be acquired or become publiclylisted on different exchanges around the world including the NASDAQ, KOSDAQ and the GEM market. Mr. Eldred has an Executive MBA from IE Business School and a BA in Foreign Service from Baylor University. - Kary Eldred自2018年起担任Living Stone Foundation董事，自2015年7月起担任首席投资官，多年来一直是活跃的私募股权投资者。在这些职位上，他曾担任多家具有首次公开募股潜力并推动其发展的公司的董事会成员，目前担任Buy IT Installing（2017年以来）和Wise King Media（2015年以来）的董事会成员。Kary Eldred也曾任职于GCT Semiconductor的董事会和审计委员会。从2011年1月到2014年10月，Eldred先生担任Altadona，S.A.的首席执行官兼董事长，这是一家位于欧洲的软件集成公司，在此之前，他是Parakletos Ventures的负责人，一家机构风险投资公司，对在纳斯达克，科斯达克和创业板市场等全球不同交易所被收购或公开上市的公司进行了多项投资。Eldred先生拥有IE Business School的执行工商管理硕士学位和Baylor University的外交服务学士学位。
- Kary Eldred is a director since 2018 and Chief Investment Officer for the Living Stones Foundation since July 2015 and has been an active private equity investor for many years. In these capacities, he serves and has served on a number of corporate boards of companies with potential for and driving toward initial public offerings and is currently serving as a board member in Buy It Installed (since 2017), Babywise and Wise King Media (since 2015). Kary Eldred also served on the board and audit committee of GCT Semiconductor. From January 2011 through October 2014, Mr. Eldred was CEO & Chairman of Altadona, S.A. a software integration company based in Europe and prior to that was a principal in Parakletos Ventures, an institutional venture capital firm with several investments in companies that went on to be acquired or become publiclylisted on different exchanges around the world including the NASDAQ, KOSDAQ and the GEM market. Mr. Eldred has an Executive MBA from IE Business School and a BA in Foreign Service from Baylor University.
- Kevin D. Freeman
-
Kevin D. Freeman， 自2011年5月起担任董事。持有特许金融分析师称号，是Cross Consulting and Services, LLC（成立于2004年的投资顾问和咨询公司）的行政总裁。他也是纽约时报有关股票市场和经济的畅销书作者。曾担任Separate Account Solutions, Inc.的董事长，从1991年到2000年在Franklin Templeton Investment Services担任多个职位。他获得俄克拉荷马州塔尔萨的塔尔萨大学的工商管理学士学位。
Kevin D. Freeman a director since May 2011, holds the Chartered Financial Analyst designation and is Chief Executive Officer of Cross Consulting and Services, LLC, an investment advisory and consulting firm founded in 2004. He is also author of a New York Times best selling book about the stock market and economy and the host of a television program (Economic War Room with Kevin Freeman) that airs on BlazeTV. Formerly he was Chairman of Separate Account Solutions, Inc. and held several offices at Franklin Templeton Investment Services from 1991 to 2000. He holds a B.S. in business administration from University of Tulsa, Tulsa, Oklahoma. - Kevin D. Freeman， 自2011年5月起担任董事。持有特许金融分析师称号，是Cross Consulting and Services, LLC（成立于2004年的投资顾问和咨询公司）的行政总裁。他也是纽约时报有关股票市场和经济的畅销书作者。曾担任Separate Account Solutions, Inc.的董事长，从1991年到2000年在Franklin Templeton Investment Services担任多个职位。他获得俄克拉荷马州塔尔萨的塔尔萨大学的工商管理学士学位。
- Kevin D. Freeman a director since May 2011, holds the Chartered Financial Analyst designation and is Chief Executive Officer of Cross Consulting and Services, LLC, an investment advisory and consulting firm founded in 2004. He is also author of a New York Times best selling book about the stock market and economy and the host of a television program (Economic War Room with Kevin Freeman) that airs on BlazeTV. Formerly he was Chairman of Separate Account Solutions, Inc. and held several offices at Franklin Templeton Investment Services from 1991 to 2000. He holds a B.S. in business administration from University of Tulsa, Tulsa, Oklahoma.
- Benjamin S. Carson, Sr.
-
Benjamin S. Carson, Sr.，自1997年在凯洛格任职。从1984年到2013年，他是霍普金斯医学院的小儿神经外科主任和教授，他现在在这里担任名誉教授。他在约翰霍普金斯儿童中心执导小儿神经外科超过25年。他也是一个多才多艺的作家和进行频繁的各种主题的演讲，包括小儿神经内科，儿童动机和自助，社区参与。他是好市多仓储公司的董事。
Benjamin S. Carson, Sr. a director since 2023, served as the 17th Secretary of the U.S. Department of Housing and Urban Development ("HUD") from 2017 to 2021. Dr. Carson is a world renowned neurosurgeon who prior to serving as HUD Secretary was involved with more than 15,000 surgical procedures and was the recipient of numerous awards, including the Presidential Medal of Freedom, more than 70 honorary doctorate degrees and the Spingarn Medal, the NAACP's highest honor. Dr. Carson serves on the Board of Directors for D.R. Horton, Inc. (NYSE: DHI), Covenant Logistics Group, Inc. (NASDAQ: CVLG), and Sinclair Broadcast Group, Inc. (NASDAQ: SBGI). In addition, Dr. Carson previously served on the Board of Directors of both The Kellogg Company (NYSE: K) and Costco Wholesale Corporation (NASDAQ: COST). Dr. Carson is the founder and current Chairman of the American Cornerstone Institute. Dr. Carson is on the Board of Directors of the Carson Scholars Fund, an organization he and his wife, Mrs. Candy Carson, founded in 1994. Throughout his distinguished career, Dr. Carson contributed to the field of medicine through the thousands of surgeries he performed and the many leadership positions he held, including serving as Director of the Division of Pediatric Neurosurgery at The Johns Hopkins Medical Institutions from 1984 to 2013 as well a Professor of Neurological Surgery, Oncology, Plastic Surgery, and Pediatrics at The Johns Hopkins Medical Institutions from 1999 to 2013. - Benjamin S. Carson, Sr.，自1997年在凯洛格任职。从1984年到2013年，他是霍普金斯医学院的小儿神经外科主任和教授，他现在在这里担任名誉教授。他在约翰霍普金斯儿童中心执导小儿神经外科超过25年。他也是一个多才多艺的作家和进行频繁的各种主题的演讲，包括小儿神经内科，儿童动机和自助，社区参与。他是好市多仓储公司的董事。
- Benjamin S. Carson, Sr. a director since 2023, served as the 17th Secretary of the U.S. Department of Housing and Urban Development ("HUD") from 2017 to 2021. Dr. Carson is a world renowned neurosurgeon who prior to serving as HUD Secretary was involved with more than 15,000 surgical procedures and was the recipient of numerous awards, including the Presidential Medal of Freedom, more than 70 honorary doctorate degrees and the Spingarn Medal, the NAACP's highest honor. Dr. Carson serves on the Board of Directors for D.R. Horton, Inc. (NYSE: DHI), Covenant Logistics Group, Inc. (NASDAQ: CVLG), and Sinclair Broadcast Group, Inc. (NASDAQ: SBGI). In addition, Dr. Carson previously served on the Board of Directors of both The Kellogg Company (NYSE: K) and Costco Wholesale Corporation (NASDAQ: COST). Dr. Carson is the founder and current Chairman of the American Cornerstone Institute. Dr. Carson is on the Board of Directors of the Carson Scholars Fund, an organization he and his wife, Mrs. Candy Carson, founded in 1994. Throughout his distinguished career, Dr. Carson contributed to the field of medicine through the thousands of surgeries he performed and the many leadership positions he held, including serving as Director of the Division of Pediatric Neurosurgery at The Johns Hopkins Medical Institutions from 1984 to 2013 as well a Professor of Neurological Surgery, Oncology, Plastic Surgery, and Pediatrics at The Johns Hopkins Medical Institutions from 1999 to 2013.
- Harold H. Shlevin
-
Harold H. Shlevin博士于2020年9月2日从Galectin Therapeutics Inc.总裁兼首席执行官职位上退休，该职位自2018年6月14日起担任；不过，Shlevin博士与公司签订的咨询协议有效期至2021年12月31日。Shlevin博士此前于2012年10月1日起担任Galectin Therapeutics Inc.首席运营官兼秘书。Shlevin博士自2009年11月以来一直受雇于佐治亚理工学院先进技术开发中心，担任生物科学商业化工作的负责人和经理，在那里他协助教师确定值得商业化的技术，促进新的初创生物科学公司的形成，并指导新的公司管理。2008年10月至2009年11月，他担任Altea Therapeutics公司的运营和商业开发主管，该公司是一家先进的药物输送公司，专注于通过皮肤输送治疗水平的水溶性生物治疗药物和小药物。在Altea，他负责药物研发、临床研究、法规事务、工程、临床和商业制造、质量保证、信息技术、设施运营和财务。2006年7月至2008年9月，Shlevin博士担任Tikvah Therapeutics，Inc.的总裁兼首席执行官，该公司是一家专注于神经科学疗法后期开发的初创制药企业。2000年5月至2006年1月，他担任Solvay Pharmaceuticals，Inc.（美国）总裁兼首席执行官。2006年1月，他在Solvay Pharmaceuticals，SA晋升为全球高级副总裁，同时也是Solvay Pharmaceuticals，SA的董事会成员。在此之前，Shlevin博士曾于2004年至2016年6月在Cardiome制药公司（纳斯达克股票代码：CRME）董事会任职，该公司现名为Correvio Pharma Corp.（纳斯达克股票代码：CORV）。他曾任薪酬委员会主席、公司治理委员会和审计委员会成员。
Harold H. Shlevin retired from being Galectin Therapeutics Inc. President and Chief Executive Officer on September 2, 2020, a position he had held since June 14, 2018; however, Dr. Shlevin has entered into a consulting agreement with the Company which ran through December 31, 2021. Dr. Shlevin previously served as Galectin Therapeutics Inc. Chief Operating Officer and Secretary from October 1, 2012. Dr. Shlevin previously had been employed at the Georgia Institute of Technology's Advanced Technology Development Center as Principle and Manager of bioscience commercialization efforts since November 2009, where he has assisted faculty in identifying technology worthy of commercialization, catalyzed formation of new start up bioscience companies, and mentored new company management. From October 2008 to November 2009, he served as Head of Operations and Commercial Development for Altea Therapeutics Corporation, an advanced drug delivery company focused on the delivery of therapeutic levels of water soluble biotherapeutics and small drugs through the skin. At Altea, he was responsible for pharmaceutical research and development, clinical research, regulatory affairs, engineering, clinical and commercial manufacturing, quality assurance, information technology, facility operations and finance. From July 2006 to September 2008, Dr. Shlevin served as the President and Chief Executive Officer of Tikvah Therapeutics, Inc., a start up pharmaceutical enterprise focused on later stage development of neuroscience therapeutics. From May 2000 to January 2006, he served as President and CEO of Solvay Pharmaceuticals, Inc. (US). In January 2006, he was promoted to a global senior Vice President role within Solvay Pharmaceuticals, SA and member of the Board of Solvay Pharmaceuticals, SA. Previously, Dr. Shlevin served on the Board of Directors of Cardiome Pharma Corporation (NASDAQ: CRME), now known as Correvio Pharma Corp. (NASDAQ: CORV) from 2004 to June 2016. He was Chair of the Compensation Committee and member of the Corporate Governance Committee and Audit Committees. Dr. Shlevin currently serves on the Board of Directors of Moonlight Therapeutics. - Harold H. Shlevin博士于2020年9月2日从Galectin Therapeutics Inc.总裁兼首席执行官职位上退休，该职位自2018年6月14日起担任；不过，Shlevin博士与公司签订的咨询协议有效期至2021年12月31日。Shlevin博士此前于2012年10月1日起担任Galectin Therapeutics Inc.首席运营官兼秘书。Shlevin博士自2009年11月以来一直受雇于佐治亚理工学院先进技术开发中心，担任生物科学商业化工作的负责人和经理，在那里他协助教师确定值得商业化的技术，促进新的初创生物科学公司的形成，并指导新的公司管理。2008年10月至2009年11月，他担任Altea Therapeutics公司的运营和商业开发主管，该公司是一家先进的药物输送公司，专注于通过皮肤输送治疗水平的水溶性生物治疗药物和小药物。在Altea，他负责药物研发、临床研究、法规事务、工程、临床和商业制造、质量保证、信息技术、设施运营和财务。2006年7月至2008年9月，Shlevin博士担任Tikvah Therapeutics，Inc.的总裁兼首席执行官，该公司是一家专注于神经科学疗法后期开发的初创制药企业。2000年5月至2006年1月，他担任Solvay Pharmaceuticals，Inc.（美国）总裁兼首席执行官。2006年1月，他在Solvay Pharmaceuticals，SA晋升为全球高级副总裁，同时也是Solvay Pharmaceuticals，SA的董事会成员。在此之前，Shlevin博士曾于2004年至2016年6月在Cardiome制药公司（纳斯达克股票代码：CRME）董事会任职，该公司现名为Correvio Pharma Corp.（纳斯达克股票代码：CORV）。他曾任薪酬委员会主席、公司治理委员会和审计委员会成员。
- Harold H. Shlevin retired from being Galectin Therapeutics Inc. President and Chief Executive Officer on September 2, 2020, a position he had held since June 14, 2018; however, Dr. Shlevin has entered into a consulting agreement with the Company which ran through December 31, 2021. Dr. Shlevin previously served as Galectin Therapeutics Inc. Chief Operating Officer and Secretary from October 1, 2012. Dr. Shlevin previously had been employed at the Georgia Institute of Technology's Advanced Technology Development Center as Principle and Manager of bioscience commercialization efforts since November 2009, where he has assisted faculty in identifying technology worthy of commercialization, catalyzed formation of new start up bioscience companies, and mentored new company management. From October 2008 to November 2009, he served as Head of Operations and Commercial Development for Altea Therapeutics Corporation, an advanced drug delivery company focused on the delivery of therapeutic levels of water soluble biotherapeutics and small drugs through the skin. At Altea, he was responsible for pharmaceutical research and development, clinical research, regulatory affairs, engineering, clinical and commercial manufacturing, quality assurance, information technology, facility operations and finance. From July 2006 to September 2008, Dr. Shlevin served as the President and Chief Executive Officer of Tikvah Therapeutics, Inc., a start up pharmaceutical enterprise focused on later stage development of neuroscience therapeutics. From May 2000 to January 2006, he served as President and CEO of Solvay Pharmaceuticals, Inc. (US). In January 2006, he was promoted to a global senior Vice President role within Solvay Pharmaceuticals, SA and member of the Board of Solvay Pharmaceuticals, SA. Previously, Dr. Shlevin served on the Board of Directors of Cardiome Pharma Corporation (NASDAQ: CRME), now known as Correvio Pharma Corp. (NASDAQ: CORV) from 2004 to June 2016. He was Chair of the Compensation Committee and member of the Corporate Governance Committee and Audit Committees. Dr. Shlevin currently serves on the Board of Directors of Moonlight Therapeutics.
高管简历
中英对照 | 中文 | 英文- Joel Lewis
Joel Lewis，自2017年起担任董事，于2020年9月2日成为我们的总裁兼首席执行官。此前，他曾担任Uline，Inc.（航运，包装和工业用品的分销商）的股东服务董事总经理，他于2007年至2019年担任该职位。Lewis先生是一名财务执行官，拥有超过26年的经验，于1992年开始了他的公共会计职业生涯。任职Uline Inc.之前，Lewis从2001年到2006年担任Century America LLC税务和会计经理，从1998年到2001年担任Deloitte&Touche税务经理。Lewis先生在公共会计领域工作了十年，在那里他专注于财务报告和税收，之后他移民到专注于高净值家族企业的私人控股公司。Lewis先生拥有广泛的专业知识，包括在各种行业和学科工作，包括税收，重组，收购和私募股权投资。Lewis先生是伊利诺斯州的注册会计师。他持有the University of Illinois的会计学士学位，以及DePaul University的税务硕士学位。
Joel Lewis a director since 2017, became Galectin Therapeutics Inc. President and Chief Executive Officer on September 2, 2020. Previously, he was the Managing Director of Shareholder Services at Uline, Inc. (a distributor of shipping, packaging and industrial supplies), a position he held from 2007 through 2019. Mr. Lewis is a financial executive with over 26 years of experience and started his career in public accounting in 1992. Prior to his employment with Uline Inc., Mr. Lewis served as a Tax and Accounting Manager for Century America LLC from 2001 to 2006 and a Tax Manager for Deloitte & Touche from 1998 to 2001. After spending a decade in public accounting where he specialized in both financial reporting and taxation, Mr. Lewis migrated to privately held companies focusing on high net worth family businesses. Mr. Lewis has a wide range of expertise including working in a variety of industries and disciplines including taxation, restructuring, acquisition and private equity ventures. Mr. Lewis is a registered CPA in the state of Illinois. He holds a B.S. in Accountancy from the University of Illinois and a Masters in Taxation from DePaul University.- Joel Lewis，自2017年起担任董事，于2020年9月2日成为我们的总裁兼首席执行官。此前，他曾担任Uline，Inc.（航运，包装和工业用品的分销商）的股东服务董事总经理，他于2007年至2019年担任该职位。Lewis先生是一名财务执行官，拥有超过26年的经验，于1992年开始了他的公共会计职业生涯。任职Uline Inc.之前，Lewis从2001年到2006年担任Century America LLC税务和会计经理，从1998年到2001年担任Deloitte&Touche税务经理。Lewis先生在公共会计领域工作了十年，在那里他专注于财务报告和税收，之后他移民到专注于高净值家族企业的私人控股公司。Lewis先生拥有广泛的专业知识，包括在各种行业和学科工作，包括税收，重组，收购和私募股权投资。Lewis先生是伊利诺斯州的注册会计师。他持有the University of Illinois的会计学士学位，以及DePaul University的税务硕士学位。
- Joel Lewis a director since 2017, became Galectin Therapeutics Inc. President and Chief Executive Officer on September 2, 2020. Previously, he was the Managing Director of Shareholder Services at Uline, Inc. (a distributor of shipping, packaging and industrial supplies), a position he held from 2007 through 2019. Mr. Lewis is a financial executive with over 26 years of experience and started his career in public accounting in 1992. Prior to his employment with Uline Inc., Mr. Lewis served as a Tax and Accounting Manager for Century America LLC from 2001 to 2006 and a Tax Manager for Deloitte & Touche from 1998 to 2001. After spending a decade in public accounting where he specialized in both financial reporting and taxation, Mr. Lewis migrated to privately held companies focusing on high net worth family businesses. Mr. Lewis has a wide range of expertise including working in a variety of industries and disciplines including taxation, restructuring, acquisition and private equity ventures. Mr. Lewis is a registered CPA in the state of Illinois. He holds a B.S. in Accountancy from the University of Illinois and a Masters in Taxation from DePaul University.
- Khurram Jamil
Khurram Jamil，在2024年3月加入公司担任临床开发副总裁后，于2024年8月1日成为公司首席医疗官。在加入公司之前，Jamil博士于2015年7月至2024年2月受雇于马林克罗制药，担任肝病学副总裁，领导的开发团队在美国和日本获得了两种化合物的批准，在肝硬化及其并发症方面进行了试验，并设计和执行了肝肾综合征方面最大的试验。在其职业生涯的早期，他曾在Ikaria Inc和欧加隆制药美国公司担任医疗事务职务，在那里他领导了first-in-class疗法的成功推出，并制定了战略来评估疾病负担、成本效益以及新治疗领域中已获批准药物的价值主张。他拥有7项专利，发表了超过95篇海报和口头报告，发表了超过40篇手稿，包括在著名的新英格兰医学杂志上。Jamil医生在普外科获得董事会认证。他在新泽西州西顿霍尔大学完成了实习，并在巴基斯坦拉合尔的爱德华国王医科大学获得了工商管理硕士学位。
Khurram Jamil become the Company's Chief Medical Officer on August 1, 2024 after joining the Company as vice president of clinical development in March 2024. Prior to joining the Company, Dr. Jamil was employed at Mallinckrodt Pharmaceuticals from July 2015 to February 2024, where he was Vice President Hepatology and led the development teams that achieved approval of two compounds in the U.S. and Japan, conducted trials in liver cirrhosis and its complications, and designed and executed the largest trial in Hepatorenal Syndrome. Earlier in his career he held positions in medical affairs in Ikaria Inc and Organon Pharmaceuticals USA where he led successful launches of first in class therapies and developed strategies to assess disease burden, cost effectiveness, and value proposition of approved drugs in new therapeutic areas. He holds 7 patents, has given over 95 poster and oral presentations and published over 40 manuscripts, including in the prestigious New England Journal of Medicine. Dr. Jamil is board certified in General Surgery. He completed his residency in Seaton Hall University, NJ, and earned his M.B.B.S. from King Edward Medical University at Lahore, Pakistan.- Khurram Jamil，在2024年3月加入公司担任临床开发副总裁后，于2024年8月1日成为公司首席医疗官。在加入公司之前，Jamil博士于2015年7月至2024年2月受雇于马林克罗制药，担任肝病学副总裁，领导的开发团队在美国和日本获得了两种化合物的批准，在肝硬化及其并发症方面进行了试验，并设计和执行了肝肾综合征方面最大的试验。在其职业生涯的早期，他曾在Ikaria Inc和欧加隆制药美国公司担任医疗事务职务，在那里他领导了first-in-class疗法的成功推出，并制定了战略来评估疾病负担、成本效益以及新治疗领域中已获批准药物的价值主张。他拥有7项专利，发表了超过95篇海报和口头报告，发表了超过40篇手稿，包括在著名的新英格兰医学杂志上。Jamil医生在普外科获得董事会认证。他在新泽西州西顿霍尔大学完成了实习，并在巴基斯坦拉合尔的爱德华国王医科大学获得了工商管理硕士学位。
- Khurram Jamil become the Company's Chief Medical Officer on August 1, 2024 after joining the Company as vice president of clinical development in March 2024. Prior to joining the Company, Dr. Jamil was employed at Mallinckrodt Pharmaceuticals from July 2015 to February 2024, where he was Vice President Hepatology and led the development teams that achieved approval of two compounds in the U.S. and Japan, conducted trials in liver cirrhosis and its complications, and designed and executed the largest trial in Hepatorenal Syndrome. Earlier in his career he held positions in medical affairs in Ikaria Inc and Organon Pharmaceuticals USA where he led successful launches of first in class therapies and developed strategies to assess disease burden, cost effectiveness, and value proposition of approved drugs in new therapeutic areas. He holds 7 patents, has given over 95 poster and oral presentations and published over 40 manuscripts, including in the prestigious New England Journal of Medicine. Dr. Jamil is board certified in General Surgery. He completed his residency in Seaton Hall University, NJ, and earned his M.B.B.S. from King Edward Medical University at Lahore, Pakistan.
- Jack W. Callicutt
Jack W. Callicutt，于2013年7月1日成为Galectin Therapeutics Inc.首席财务官。从2012年8月到2013年6月，Callicutt先生是REACH Health，Inc.的首席财务官，该公司是一家远程医疗技术公司，总部位于佐治亚州阿尔法利塔。从2010年4月到2012年8月，Callicutt先生是Vystar Corporation的首席财务官，Vystar Corporation是一家上市公司，拥有从天然橡胶胶乳中去除抗原蛋白的专有技术。在此之前，Callicutt先生是IVOX，Inc.、Tikvah Therapeutics和Coraut Genetics的首席财务官，后者是一家上市的生物技术公司，该公司正在开发用于治疗心血管疾病的基因疗法。Callicutt Previoly先生在公共会计领域工作了十几年，最近在德勤担任高级经理，他在1989年至2003年期间专门研究科技公司。Callicutt先生是一名注册会计师，以优异成绩毕业于德尔塔州立大学，获得会计和计算机信息系统学士学位。
Jack W. Callicutt became Galectin Therapeutics Inc. Chief Financial Officer on July 1, 2013. From August 2011 through June 2012, Mr. Callicutt was the Chief Financial Officer of REACH Health, Inc., a telemedicine technology company headquartered in Alpharetta, GA. From April 2010 through August 2012, Mr. Callicutt was the Chief Financial Officer of Vystar Corporation, a publicly traded company that holds proprietary technology to remove antigenic proteins from natural rubber latex. Prior to that Mr. Callicutt was Chief Financial Officer of IVOX, Inc., Tikvah Therapeutics and Corautus Genetics, a publicly traded biotechnology company which was developing gene therapy for treatment of cardiovascular disease. Mr. Callicutt previously spent more than fourteen years in public accounting, most recently as a senior manager at Deloitte, where he specialized in technology companies from 1989 to 2003. Mr. Callicutt is a Certified Public Accountant and graduated with honors from Delta State University with a B.B.A. in accounting and computer information systems.- Jack W. Callicutt，于2013年7月1日成为Galectin Therapeutics Inc.首席财务官。从2012年8月到2013年6月，Callicutt先生是REACH Health，Inc.的首席财务官，该公司是一家远程医疗技术公司，总部位于佐治亚州阿尔法利塔。从2010年4月到2012年8月，Callicutt先生是Vystar Corporation的首席财务官，Vystar Corporation是一家上市公司，拥有从天然橡胶胶乳中去除抗原蛋白的专有技术。在此之前，Callicutt先生是IVOX，Inc.、Tikvah Therapeutics和Coraut Genetics的首席财务官，后者是一家上市的生物技术公司，该公司正在开发用于治疗心血管疾病的基因疗法。Callicutt Previoly先生在公共会计领域工作了十几年，最近在德勤担任高级经理，他在1989年至2003年期间专门研究科技公司。Callicutt先生是一名注册会计师，以优异成绩毕业于德尔塔州立大学，获得会计和计算机信息系统学士学位。
- Jack W. Callicutt became Galectin Therapeutics Inc. Chief Financial Officer on July 1, 2013. From August 2011 through June 2012, Mr. Callicutt was the Chief Financial Officer of REACH Health, Inc., a telemedicine technology company headquartered in Alpharetta, GA. From April 2010 through August 2012, Mr. Callicutt was the Chief Financial Officer of Vystar Corporation, a publicly traded company that holds proprietary technology to remove antigenic proteins from natural rubber latex. Prior to that Mr. Callicutt was Chief Financial Officer of IVOX, Inc., Tikvah Therapeutics and Corautus Genetics, a publicly traded biotechnology company which was developing gene therapy for treatment of cardiovascular disease. Mr. Callicutt previously spent more than fourteen years in public accounting, most recently as a senior manager at Deloitte, where he specialized in technology companies from 1989 to 2003. Mr. Callicutt is a Certified Public Accountant and graduated with honors from Delta State University with a B.B.A. in accounting and computer information systems.